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Objective: To evaluate the performance of the
FreeStyle Libre Flash continuous glucose monitoring
(FSL-CGM) system against established central
laboratory methods.
Research design and methods: 20 subjects
(8 type 1 diabetes mellitus, 12 type 2 diabetes
mellitus) were analyzed. FSL-CGM sensor
measurements (inserted in arm and abdomen) were
compared with capillary blood glucose results analyzed
with StatStrip as semigold standard. The glucose
response after a standardized oral glucose load was
measured by FSL-CGM and capillary samples analyzed
by perchloric acid hexokinase (PCA-HK) method,
StatStrip and FSL test strip (FSLC), and a commonly
used CGM system (iPro2).
Results: FSL-CGM arm sensor readings showed
85.5% of paired readings falling within Clarke Error
Grid (ISO 15197:2013) zone A when compared with
StatStrip. For FSL-CGM abdomen and FSLC, these
percentages were 64% and 98%, respectively. The
overall correlation of FSL-CGM in the arm and the
StatStrip indicates a performance with lower results
with the FSL-CGM in the arm than expected based on
the StatStrip in the lower glucose ranges, and higher
results than expected in the higher ranges. Following a
standardized glucose load, a slower rise in glucose
level was observed for FSL-CGM arm as compared
with PCA-HK, StatStrip, FSLC, and iPro2 during the
first 45–60 min after glucose load ingestion.
Conclusions: Certain matters need attention while
using the FSL-CGM in daily life including the observed
lower values in the lower ranges, and the
underestimation of the effect of a meal on glucose
response. These effects of such deviations can partly
be overcome by optimizing the available user
instructions.
Trial registration number: TC5348; results.
INTRODUCTION
Self-monitoring of blood glucose levels
requires intermittent capillary blood sam-
pling and a blood glucose measurement
device. However, many patients experience
barriers to frequent testing, among others
including the pain and discomfort associated
with the ﬁnger-stick blood samples along
with accumulated trauma to the ﬁngers.
Also, intermittent blood glucose monitoring
through intermittent capillary blood sam-
pling provides only snapshots of glucose
concentrations.
Another important point of attention is
the accuracy of the strips used to measure
capillary blood glucose concentrations.
International standards have agreed on
several criteria with regards to accuracy: an
accuracy of ±15% for glucose levels
≥100 mg/dL and ±15 mg/dL for glucose
levels <100 mg/dL of the actual blood
glucose level are the most relevant criteria
from a patient point of view,1 since
Significance of this study
What is already known about this subject?
FreeStyle Libre Flash continuous glucose monitor-
ing (FSL-CGM) is an alternative approach to
glucose monitoring, more or less comparable to
continuous glucose monitoring; independent valid-
ation testing has not been performed yet. Its accur-
acy is inadequately studied.
What are the new findings?
Accuracy of FSL-CGM is moderate in comparison to
standard glucose measurement techniques,
showing lower than actual results in the lower
ranges, and higher than actual results in the higher
ranges; after standardized glucose load glucose
measurement results lag in comparison with other
glucose measurement techniques. In general, users
are satisfied.
How might these results change the focus of
research or clinical practice?
Results of the FSL-CGM should always be consid-
ered in clinical context; when in doubt, use another
glucose measurement technique to confirm or
refute the reported FSL-CGM glucose concentration.
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hypoglycemias do have the most immediate impact on
patient’s well-being and the degree of hypoglycemia
does inﬂuence the measures needed to counteract the
hypoglycemia.
In the past 15 years, continuous glucose monitoring
(CGM) systems have become available.2 These CGM
systems measure interstitial ﬂuid glucose levels at rather
closely spaced intervals to provide semicontinuous infor-
mation on glucose levels, allowing identiﬁcation and sig-
naling of glucose level ﬂuctuations to a degree that
cannot be obtained with intermittent capillary blood
glucose measurements. While improved glycemic
control has been demonstrated with the use of CGM
systems,3–5 CGM accuracy also remains a challenge; most
of the available systems need calibrating at least twice
daily to allow a sufﬁciently reliable correlation between
interstitial and capillary glucose results. Nevertheless,
with the advances in the development of highly accurate
and easy to use CGM systems, the ultimate use of ‘artiﬁ-
cial pancreas’ moves closer to become a reality.6
Recently, a different variety of continuous glucose
monitoring (CGM; FreeStyle Libre Flash (FSL-CGM),
Abbot Diabetes Care, Alameda, California, USA) for
interstitial glucose ﬂuid monitoring has been introduced
in Europe that is compact, lightweight, has a 2-week
period of use, and according to the producer does not
require calibration by the user (factory-calibrated). This
ﬂash glucose monitoring system measures interstitial
glucose via disposable electronics and a subcutaneous
sensor, with a button-like structure ﬁrmly adhering to
the skin to allow the inserted sensor to stay in place.
The sensor is put in place by a single-use applicator, and
automatically measures glucose every minute for up to
14 days. Scanning of the sensor by a separate reader col-
lects the glucose measurements and trend at the
moment of scanning plus up to 8 hours of prior read-
ings every 15 min. The reader used for FSL-CGM also
supports glucose and ketone capillary blood measure-
ments using FreeStyle Precision glucose/ketone strips.
In principle, the glucose sensing technique is based on
the technique of the FreeStyle Navigator, which has
been shown to be a reliable CGM measurement tech-
nique.7–9
Whenever a new CGM device becomes available, it is
essential to critically evaluate its accuracy and usability.
Independent accuracy assessments of the FSL-CGM are
scarce; previous assessments were performed comparing
the FSL-CGM to capillary blood evaluated with a point of
care (POC) measurement.10 Whether such a comparison
can be seen as sufﬁcient accurate remains to be seen,
however. As already alluded, capillary measurements are
allowed to deviate for a maximum of 15% for glucose
levels ≥100 mg/dL and ±15 mg/dL for glucose levels
<100 mg/dL.1 Furthermore, glucose measurements with
POC devices can be highly inaccurate, especially in critic-
ally ill patients.11–13 Therefore, the use of an appropriate
reference method is a key factor when assessing the
quality of POC glucose device accuracy studies.14
The present study was designed to assess the accuracy
and usability of the FSL-CGM by comparing its scanned
sensor results with various standardized reference
methods in a subjects with type 1 diabetes mellitus
(T1DM), type 2 diabetes mellitus (T2DM) and subjects
without diabetes; this article presents the results in the
diabetes population.
RESEARCH DESIGN AND METHODS
Study design
This study had a prospective design. Inclusion and study
procedures took place at the Department of Internal
Medicine of the Isala hospital (Zwolle, the Netherlands)
in the period between 30 August 2015 to 29 September
2015. Primary aim of this study was to establish the
accuracy of the FSL-CGM against an established central
laboratory technique.
The study was performed according to Good Clinical
Practice and the Principles of the Declaration of
Helsinki. The Ethics Review Committee of the hospital
approved the protocol and written informed consent
was obtained from every participant prior to enrolment.
The study protocol was registered prior to the start of
the study (http://www.trialregister.nl (TC 5348)).
Patients
Persons with T1DM, T2DM, and persons without DM
between 18 and 75 years of age who were able to
undergo the requested study procedures were eligible
for study participation. Main exclusion criteria were the
inability to understand the Dutch language and the
presence of a severe or unstable medical condition. In
this article only the results in persons with T1DM and
T2DM are described.
Study procedures
The overall study duration for each participant was
14 days. After obtaining informed consent, baseline
characteristics were collected using a standardized case
record form during the ﬁrst study visit. Additionally, one
FSL-CGM sensor was inserted on the back of the upper
arm and one in the abdominal wall. In addition, a retro-
spectively calibrated blinded CGM (iPro2 Professional
CGM; Medtronic, Northridge, Pennsylvania, USA)
device was inserted in the abdominal wall, not to be
seen as a comparison as gold standard, but to allow com-
paring two CGM systems. The FSL-CGMs remained in
situ for 14 days and the blinded CGM for 7 days. Patients
were instructed to perform a total of four capillary self-
measurements of blood glucose using the FSLC, the
FSL-CGM test strip and the StatStrip Xpress monitoring
system (Nova Biomedical, Waltham, Massachusetts,
USA). In our facility, the StatStrip POC glucose measure-
ment systems (Nova Biomedical, Waltham,
Massachusetts, USA) have been traced and aligned to
the highest level order of methodology: isotope dilution
gas chromatography, mass spectrometry.15 The preferred
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testing sequence was on waking, before lunch, before
dinner and at bedtime. Following each test, subjects
were asked to report the blood glucose results in a diary
along with the glucose results of the FSL-CGM scans
(using separate reading devices for the arm and abdom-
inal wall FSL-CGM). It was recommended to conﬁrm
the glucose value with a capillary measurement in case
of (imminent and/or suspected) hypoglycemia, glucose
levels changing rapidly, or when symptoms did not
match the systems reading.
All device-related procedures were performed by one
trained investigator (MJF).
The second study visit was performed during the 14-day
study period, at least 1 day after insertion of the FSL-CGMs
and the iPro2 device. During this 4-hour in-clinic visit, an
oral glucose challenge test with repeated blood sampling
was performed. Capillary blood samples were taken at 0,
15, 30, 45, 60, 75 and 90 min after ingestion of a 75 g oral
glucose load. Capillary blood glucose tests during the
glucose challenge test were performed within a 2 min
time frame in relation to the FSL-CGM readings, and the
iPro2 readings. Capillary blood analyses were performed
using StatStrip, FSL test strip and the reference method:
perchloric acid hexokinase (PCA-HK) method (Roche
Modular P800, Roche Diagnostics GmbH, Mannheim,
Germany).16 Body composition was measured and fat per-
centage estimated by using an Omron BF306.
Outcomes
Primary outcome was the accuracy of the FSL-CGM in
the arm against StatStrip measurements during the
14-day study period and the results of the glucose load
testing. Correlation between FSL-CGM and StatStrip was
calculated using Clarke Error Grid analysis for the com-
bined T1DM and T2DM group.
The readings of the FSL-CGM in the arm after the
75 g glucose load were compared with the FSL test strip,
the StatStrip, and the PCA-HK method as comparison
with capillary blood glucose measurements, and with the
iPro2 as a comparison with another CGM device. The
iPro2 was retrospectively calibrated (1–3 hours) before
starting the glucose load test. No data from the glucose
load test were used for calibration of the iPro2.
The test results of FSL-CGM in the abdominal wall
were assessed in an identical way, to assess the degree of
accuracy of the FSL-CGM device on an alternative site.
Statistical methods and ethical considerations
Results are expressed as mean (with SD) or median
(with IQR) for normally distributed and non-normally
distributed data, respectively. A signiﬁcance level of 5%
(two-sided) was used. Normality was examined with Q-Q
plots.
Measurements were also assessed through mean abso-
lute differences (MAD) and mean absolute relative dif-
ferences (MARD) for all ranges.
For the glucose challenge test, repeated measures
mixed-model analyses were applied to assess MARD
between FSL-CGM and PCA-HK, with subjects as a
random effect and type of diabetes as ﬁxed effect.
Wilcoxon signed-rank test were applied for paired differ-
ences between methods at the different time points, that
is, 0, 15, 30, 45, 60, 75 and 90 min. Outcomes from
FSL-CGM and capillary blood glucose readings were
superimposed on the error grids as described by Clarke
et al.17 The point accuracy of sensor-based glucose values
versus ﬁnger stick blood glucose was determined as per
cent within consensus error grid zone A. Bootstrap ana-
lyses were performed to determine 95% CIs around the
percentage of values within zone A. Values in zones A
and B are deemed clinically acceptable, whereas those
in zones C, D and E are considered potentially unsafe.
Analyses were performed using SPSS (IBM SPSS
Statistics for Windows, V.20.0, Armonk, New York, USA:




A total of 28 subjects were included in this study, 8 sub-
jects with T1DM, 12 subjects with T2DM (in total 20 sub-
jects with DM) and 8 non-diabetic subjects. Two persons
(one T1DM, one T2DM) did not end the study due to a
detachment of the sensors of the FSL-CGM, and one
T1DM withdrew from the study because of personal
reasons. Therefore, the presented results represent 18
subjects with diabetes in the comparison study (7 T1DM,
11 T2DM); furthermore, 17 out of 18 subjects (6 T1DM,
11 T2DM) successfully ﬁnished the 75 g glucose load
testing. Baseline characteristics are presented in table 1.
Table 1 Baseline characteristics
Type 1 diabetes Type 2 diabetes
N=8 N=12
Age (years) 63 [24–74] 56 [39–65]
Female sex (%) 3 (38) 3 (25)
BMI (kg/m2) 23.2 [21.6–24.5] 28.3 [26.4–30.7]








HbA1c (mmol/mol) 59 [46–70] 55 [42–82]
Presence of microvascular complications
Nephropathy (n) 0 1
Neuropathy (n) 2 4
Retinopathy (n) 2 1
Diabetes duration
(years)
14 [7–24] 13 [4–25]
Data are presented as n (%), mean (SD) or median [range].
BD, twice daily mix insulin; BMI, body mass index; CSII,
continuous subcutaneous insulin infusion; HbA1c, glycated
hemoglobin; MDI, multiple daily injections; SU, sulfonylurea
derivate.
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Accuracy of FSL-CGM versus StatStrip
Figure 1 demonstrates the Clarke Error Grid analyses
(ISO 15197: 2013) of the StatStrip and coincident read-
ings of FSL-CGM arm, FSL-CGM abdomen and FSLC in
the combined population of 18 subjects with T1DM and
T2DM (ﬁgure 1). For the paired StatStrip-FSL-CGM arm
readings, the percentages of results in zone A was 85.5
(95% CI 77.6 to 89.5) as determined by bootstrap
analyses.
FSL-CGM in the arm versus abdomen and FSL-CGM arm
versus other techniques
Percentages of paired readings falling in zone A were
found to be substantially lower for FSL-CGM abdomen,
that is, 63.9% (95% CI 56.8% to 68.7; ﬁgure 1).
As presented in ﬁgure 1, comparing the FSLC test
strip results with the StatStrip showed a tight correlation
between both glucose measurement techniques, the per-
centages of results in zone A being 97.8% (95% CI
97.1% to 98.6%) as determined by bootstrap analyses.
The percentages of results in zone B was 2.0% and in
zone C 0.2%.
The overall correlation of FSL-CGM in the arm and
the StatStrip indicates a performance with lower results
with the FSL-CGM in the arm than expected based on
the StatStrip in the lower glucose ranges, and higher
results than expected in the higher ranges. This resulted
in a correlation equation of Y=1.07X−13.48. Comparing
glucose measurement data at various ranges conﬁrmed
this observation: MAD and MARD at these ranges are
shown for the comparisons of FSL-CGM and FSL capil-
lary, and for FSL-CGM versus StatStrip (table 2).
Oral glucose loading test
Part of the results of the measurements of the glucose
loading test with the FSL-CGM and the PCA-HK, real-
time CGM, FSLC glucose strip and the StatStrip are pre-
sented in ﬁgure 2. The results demonstrate a slower rise
and generally lower glucose values for the FSL-CGM as
compared with the established laboratory method
PCA-HK and StatStrip, as evidenced by signiﬁcant differ-
ences between methods at time points 15, 30, 45 and
60 min (ﬁgure 2). For patients with DM the MARD was
8.3% (95% CI 13.1% to 3.5%); 12.7% (95% CI 21.2% to
4.3%) for subjects with T1DM and 6.4% (95% CI 12.0%
to 0.7%) for subjects with T2DM.
The CGM comparator iPro2 CGM readings showed
glucose levels being comparable to those of the PCA-HK
and StatStrip on virtually all points (ﬁgure 2).
DISCUSSION
In this study, the performance of the FSL-CGM was eval-
uated against capillary blood glucose reference
Figure 1 Clarke Error Grids (ISO15197; 2013) of StatStrip and coincident FSLTab-CGM arm (upper left panel), FSL-CGM
abdomen (lower left panel) and FSLC readings (right panel) in the combined population of type 1 and 2 diabetes. Number and
percentages of paired readings within error grid zones A, B, C D and E are presented. FSL-CGM, FreeStyle Libre Flash
continuous glucose monitoring.
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measurements traced and aligned against established
laboratory methods, both in daily life practice and
during a glucose loading test. The results demonstrated
that the use by subjects with T1DM and T2DM of the
FSL-CGM in a daily life setting was associated with an
acceptable accuracy, with 85.5% and 97.8% of the
paired FSL-CGM—StatStrip readings falling within con-
sensus Clarke Error Grid zone A and clinically accept-
able zones A and B, respectively. Acceptable accuracy
could only be demonstrated for the FSL-CGM readings
in the upper arm, data obtained from the abdomen was
not reliable (only 62.9% of readings in zone A).
Findings of this study are in line with recently published
data on the performance of the FSL-CGM (85.5% and
99.0% of readings falling in error grid zone A and zones
A and B, respectively),10 and previous studies evaluating
the accuracy of other CGM systems.17–21 Furthermore,
results in the lower ranges are more or less in line with
the ﬁndings of Linong and colleagues, who found a
MAD in the ≤70 mg/dL of 14 mg/dL (translating into a
20% relative difference in that range) when comparing
FSL-CGM with the Free Precision strip capillary glucose
measurement.
In lower glucose ranges, during hypoglycemia or in
periods of rapid variation in glucose levels, values pro-
vided by CGM systems may be inaccurate.22 In our study,
lower than expected glucose values were observed in the
lower glucose ranges for the FSL-CGM compared with
reference method. This is and will remain a point of
attention for various reasons. When a user is alert and
sees a low reading in the absence of clinical signs of
hypoglycemia, glucose control with another technique is
advisable.
As an observational fact, some of the study subjects
reported low readings especially during the night, not
supported by the control measurements. Therefore, this
should also be a point of attention when on hindsight
low FSL-CGM readings are found after sleeping/in
nighttime. Again, this will not necessarily be a true rep-
resentation of the actually existing glucose concentra-
tion. Since this observation was no part of the study
design, a more formal and properly performed study is
necessary to elucidate this observation.
Accurate hypoglycemia measurements are clinically
important for obvious reasons. It is recognized that cur-
rently available CGM devices generally are least accurate
in the hypoglycemic range11 23—further reﬁnements in
technology may be required before these systems could
be used to sufﬁciently accurate warn for (impending
severe) hypoglycemia. Whether such status can ever be
reached, remains an important issue, which is not only
dependent on the efforts of the manufacturers to
improve algorithms but may also be due to the inherent
inability to predict interstitial ﬂuid changes, both in ﬂow
and in glucose concentrations (see also below).
This study also demonstrates a slower rise in glucose
levels along with an (initially) signiﬁcantly aberrant
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FSL-CGM in comparison with results obtained from the
PCA-HK and StatStrip analyses, but also in comparison
with the FSL test strip and the iPro2. Consequently, one
may underestimate the effect of a meal on the glucose
response when only taking the FSL-CGM readings into
account.
Using subcutaneous interstitial ﬂuid for glucose moni-
toring provides closeness to the vasculature while still
being minimally invasive and has become the mainstay
of CGM devices. Although sensors are evolving in the
past years, subcutaneous sensing still has inherent limita-
tions (physiological lag time, sensitivity to local ﬂuctua-
tions) and can be slow and variable.24 25 Apparently, the
producer of the iPro2 has been able to address this issue
differently compared with the producer of the
FSL-CGM; a part of the observed differences is
explained by the calibration used for the iPro2, but def-
initely not completely.
Technologies for CGM require patient education for
proper use of the device and correct interpretation of
the data.22 26 The observed deviations of the FSL-CGM
system from the norm identiﬁed in this study can partly
be addressed by appropriate patient instruction at ﬁrst
use of the device. It also places a responsibility with the
producer to bring such deviations under the attention
of the users.
The FSL-CGM has various features that distinguish the
device from currently available CGMs.27 The compact
and easy to use FSL-CGM system is factory calibrated
and does not need ﬁngers stick calibration during the
14 days of wear. FSL-CGM could be considered as CGM
on demand or a viable alternative to frequent ﬁnger
prick readings, and might also beneﬁt individuals who
have ceased sensor use due to alarm fatigue.28 Owing to
its 14-day longevity, costs are lower compared with avail-
able CGM systems,27 29 30 bringing the FSL-CGM within
easier reach for out-of-pocket expenses and reimburse-
ment systems. In line with these observations it was
stated previously that patients using the device were satis-
ﬁed with its performance with numerous reports avail-
able in patient blogs.27 It is anticipated that the
FSL-CGM system will contribute to the ability of
adequate self-management in appropriate target groups.
This study is the ﬁrst to describe the accuracy of the
FSL-CGM in a clinical and real-life setting in an inde-
pendent study. Comparisons with various blood glucose
measurement techniques are made, including the gold
standard and an often used real-time CGM method.
Figure 2 The 75 g glucose loading test. Comparison of FSL-CGM versus PCA-HK, StatStrip, FSLC test strip, and iPro2; and
PCA-HK versus FSLC test strip, and iPro2. Glucose concentrations (mg/dL; median, interquartile Q1 and Q3) at time points 0,
15, 30, 45, 60, 75 and 90 min in the combined population of type 1 and 2 diabetes. *p Value ≤0.05; **p Value ≤0.01. FSL-CGM,
FreeStyle Libre Flash continuous glucose monitoring; PCA-HK, perchloric acid hexokinase.
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Limitations should be mentioned. First and foremost,
numbers are small. In particular, the relatively low
number of readings below 80 mg/dL, due to the non-
blinded nature of our study patients were able to act on
low glucose concentrations, could be of importance with
respect to our aforementioned concerns about the inﬂu-
ence of low readings. The accuracy of the FSL in the
lower ranges, and also in the higher ranges, should be
subject of future studies which include an acceptable
amount of readings and, ideally, data concerning clinical
tests and symptoms.
Second, as our study was applied in a daily life setting,
the accuracy of the FSL-CGM could not be established
against the ‘real gold standard’ to measure arterial
blood glucose concentrations. Further study limitations
included the risk of individual subject errors in the
study procedures (eg, use of the device, reporting of
glucose results, intake study drugs, despite correct
instructions). However, we intentionally used a broad
range of methods as well as Abbott’s own FSL test strip
for comparison of the FSL-CGM.
CONCLUSIONS
Our ﬁndings indicate that the FSL-CGM system can be
used as a reasonably suitable adjunct in the management
of diabetes, but only when used if inserted in the upper
arm. In this prospective study, a reasonable accuracy of the
FSL-CGM readings in the upper arm was demonstrated
against capillary values that were traced and aligned
against recognized laboratory reference values. However,
certain matters need attention while using the FSL-CGM
in daily life including the observed lower values in the
lower ranges and higher values in the higher ranges, and
the underestimation of the effect of a meal on glucose
response. These weaknesses can partly be overcome by
optimizing the available user instructions. Further evalu-
ation is needed to identify the proper target population
most likely to beneﬁt from the FSL-CGM.
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